Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
2 papers
Compass Pathways reported early results from its first Phase 3 trial of synthetic psilocybin (COMP360) for treatment‑resistant depression. In 258 patients, the 25 mg dose showed a statistically significant improvement versus placebo on the MADRS depression scale at week 6 (a 3.6‑point difference, p < 0.001). The Data and Safety…
This review looked at published clinical trials of psilocybin for depression. It found 11 trials (six open‑label and five double‑blind randomized trials) that report rapid antidepressant and anti‑anxiety effects in some patients. The paper describes how psilocybin acts on serotonin 5‑HT2A receptors, may boost brain plasticity, and may lower brain…
